Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study

Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study

Data on use of monoclonal antibodies (mAbs) in hospitalized patients are limited. In this cross-sectional study, we evaluated the use of mAbs for early treatment of unvaccinated hospitalized patients with mild-to-moderate COVID-19. All inpatients at our center were screened on 27 October 2021. Prima...

Full description

Bibliographic Details
Main Authors: Sean W. X. Ong, Dongdong Ren, Pei Hua Lee, Stephanie Sutjipto, Christopher Dugan, Bo Yan Khoo, Jun Xin Tay, Shawn Vasoo, Barnaby E. Young, David C. Lye
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Antibiotics
Subjects:
COVID-19
SARS-CoV-2
sotrovimab
treatment
monoclonal antibody
Online Access:https://www.mdpi.com/2079-6382/11/3/345

Internet

https://www.mdpi.com/2079-6382/11/3/345

Similar Items